Amgen’s Repatha Delivers 29% MACE Reduction, LDL-C to 45 mg/dL in Diabetes
AMGN•Amgen’s Phase 3 VESALIUS-CV subgroup of 6,002 high-risk diabetes patients showed Repatha reduced 3-P MACE by 29% and 4-P MACE by 21%, achieving median LDL-C of 45 mg/dL versus 106 mg/dL. Real-world ADA data highlighted sub-60% one-year persistence with GLP-1 therapies, underscoring market opportunity for Amgen’s cardiometabolic pipeline.
1. VESALIUS-CV Subgroup Efficacy in High-Risk Diabetes
The VESALIUS-CV trial subgroup enrolled 6,002 patients with microvascular disease, insulin use or ≥10-year diabetes duration and elevated LDL-C but no prior heart attack or stroke. Repatha added to statin or other LDL-C therapy cut the composite 3-P MACE endpoint (CHD death, MI, ischemic stroke) by 29% versus placebo and the 4-P MACE endpoint (including revascularization) by 21%.
2. Robust LDL-C Lowering Achieved
Patients on Repatha reached a median LDL-C of 45 mg/dL compared with 106 mg/dL in the placebo arm, with 898 participants in a lipid sub-study confirming deep cholesterol reductions. These results underscore the potency of evolocumab in managing stubborn LDL-C levels among high-risk diabetes patients.
3. Real-World GLP-1 Treatment Gaps
Amgen’s real-world analyses at the ADA sessions revealed that persistence and adherence to GLP-1 receptor agonists remain below 60% after one year, potentially limiting HbA1c and weight benefits. These findings highlight an unmet need for therapies or support programs that sustain long-term treatment in obesity and diabetes care.
4. Implications for Amgen’s Cardiometabolic Portfolio
The robust VESALIUS-CV outcomes and documentation of GLP-1 therapy gaps position Amgen to strengthen its cardiometabolic franchise. Success with Repatha could drive broader adoption and revenue growth, while insights into treatment persistence may inform development of next-generation metabolic therapies.
